A single-blind, placebo-controlled, dose-ranging trial of oral HDV-insulin [hepatic directed vesicle-insulin] in patients with type 2 diabetes mellitus
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Diasome Pharmaceuticals
- 10 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2008 Results will be presented at ADA in June 2008 according to a Diasome Pharmaceuticals media release.
- 05 Sep 2007 New trial record.